Raw Materials & Excipients Management – Page 21

Change impact underestimated during deviation investigation – inspection questions regulators ask

A deviation can manifest symptoms that may indicate underlying issues. It’s critical for stakeholders in Production, QC, and QA to be vigilant. Some common symptoms to watch for include:Click to…

Vendor change implemented without approval during routine supplier audit – audit CAPA remediation framework

Framework for Investigating Unauthorized Vendor Change During Supplier Audit In the pharmaceutical manufacturing environment, maintaining consistency and compliance in raw material procurement is critical. A deviation that may arise is…

Change control documentation gaps during supplier change – inspection questions regulators ask

Recognizing the early warnings of change control documentation gaps is essential. Below are common symptoms that may indicate issues during a supplier change:Click to read the full article.

Audit response ineffective during regulatory inspection – how to prevent repeat supplier failures

The initial step in addressing ineffective audit responses during regulatory inspections is to identify the symptoms that indicate a potential breakdown in supplier management or raw material quality. These signals…

Unapproved material substitution during post-approval change review – inspection questions regulators ask

Identifying early warning signs that a raw material substitution has occurred or may pose a risk is crucial. Here are some indicators that should raise flags:Click to read the full…

Supplier audit findings escalated during supply disruption – supplier risk classification strategy

Observable symptoms from supplier deficiencies may surface in various settings—either on the manufacturing floor or in the quality control laboratory. Recognizing these symptoms promptly is crucial to mitigating risk. Here…

Specification change not communicated during deviation investigation – inspection questions regulators ask

Recognizing the symptoms associated with uncommunicated specification changes is the first step in any effective response plan. Symptoms can manifest in various ways at both the production floor and laboratory…

Audit response ineffective during routine supplier audit – how to prevent repeat supplier failures

How to Address Ineffective Audit Responses During Routine Supplier Assessments In the highly regulated pharmaceutical landscape, maintaining the integrity of raw material supply chains is paramount. An ineffective audit response…

Change control documentation gaps during deviation investigation – CAPA to prevent repeat failures

Addressing Documentation Gaps in Change Control During Deviation Investigations In the pharmaceutical manufacturing environment, the integrity of raw material change control is paramount. A failure in documentation can lead to…

Supplier audit findings escalated during regulatory inspection – audit CAPA remediation framework

Supplier audit findings can manifest through various symptoms that are typically observed on the manufacturing floor or during laboratory testing phases. Here are some indicators to watch for:Click to read…

Raw material change implemented without assessment during regulatory inspection – preventing batch rejection and recalls

Recognizing early signals of a potential issue with raw material changes is crucial in preventing larger problems. Symptoms can manifest in a variety of ways, including:Click to read the full…

Vendor change implemented without approval during routine supplier audit – evidence pack for vendor oversight

Detecting an unauthorized vendor change is the first step in managing potential risks. Symptoms may manifest as discrepancies in raw material specifications, unexpected variations in product performance, or failure to…